Literature DB >> 4058753

Parkinson's disease and hypertension: chronic bromocriptine treatment.

J L Montastruc, B Chamontin, A Rascol.   

Abstract

We studied the effects of bromocriptine therapy (mean dosage, 56.0 mg daily) for 12 months in five patients with both Parkinson's disease and hypertension. Therapy improved neurologic manifestations and reduced both supine and standing systolic blood pressures and standing diastolic blood pressure with no consistent change in heart rate. Transient episodes of orthostatic hypotension appeared in two cases. Domperidone (60 mg daily for 1 month) did not abolish the antihypertensive effect of bromocriptine, suggesting that central dopaminergic or alpha-adrenolytic mechanisms are involved in this effect. Bromocriptine may be useful in the treatment of hypertension in patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4058753     DOI: 10.1212/wnl.35.11.1644

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Cardiovascular reflexes and autonomic dysfunction in Parkinson's disease.

Authors:  G Meco; L Pratesi; V Bonifati
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

2.  Autonomic disturbances and cardiovascular reflexes in idiopathic Parkinson's disease.

Authors:  S M Ludin; U H Steiger; H P Ludin
Journal:  J Neurol       Date:  1987-10       Impact factor: 4.849

3.  Differences in drug prescribing patterns in elderly parkinsonian patients identified at hospital admission.

Authors:  V F Trewin; C J Lawrence; A J Abdulla; V R Pearce; G B Veitch; M Roach
Journal:  Pharm World Sci       Date:  1997-12

4.  Stimulation of sympathetic activity by carbon dioxide in patients with autonomic failure compared to normal subjects.

Authors:  S Braune; A Hetzel; A Prasse; K Dohms; B Guschlbauer; C H Lücking
Journal:  Clin Auton Res       Date:  1997-12       Impact factor: 4.435

5.  Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus.

Authors:  Bindu Chamarthi; Aaron Vinik; Michael Ezrokhi; Anthony H Cincotta
Journal:  Endocrinol Diabetes Metab       Date:  2019-11-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.